Investment Rating - The report assigns a "Buy" rating for the company for the first time [1]. Core Insights - The company, Shanghai Yizhong, has a leading position in nanomedicine drug delivery technology and is strategically developing a multi-target antibody platform. Its core product, paclitaxel polymer micelles, was approved for marketing in China in 2021 and entered the medical insurance directory in 2024, indicating strong growth potential [4][14]. - The company is expected to see significant revenue growth driven by its core product and ongoing research pipeline, with projected net profits of 102 million, 131 million, and 184 million yuan for 2025, 2026, and 2027 respectively [4][8]. Summary by Sections 1. Company Overview - Shanghai Yizhong was established in September 2009 and focuses on the development of innovative anti-tumor drugs. It has a robust research and development capability supported by a team with expertise in high polymer materials and drug formulation [14][17]. - The company has developed a unique nanodrug delivery system (NDDS) that enhances the safety and efficacy of existing drugs, with its core product being the paclitaxel polymer micelle, classified as a new drug of category 2.2 in China [14][31]. 2. Product Analysis: Paclitaxel Micelles - The paclitaxel polymer micelle is the first approved micelle formulation in China, offering advantages in efficacy and patient compliance. It is the only micelle formulation that has been approved and included in the medical insurance directory, which is expected to drive future sales growth [5][42]. - The product has shown significant improvements in clinical outcomes compared to previous formulations, with a notable objective response rate (ORR) of 50% and a median progression-free survival (mPFS) of 6.4 months [36][35]. 3. Pipeline Development: PD-1 Triple Antibody - The company is developing YXC-001, a PD-1/VEGF/IL-2 triple antibody, which is the only one of its kind in clinical development. It is expected to file for IND approval by the end of 2025 [6][47]. - The PD-1/VEGF/IL-2 triple antibody aims to enhance overall survival (OS) for patients, leveraging the synergistic effects of combining multiple targets [57][53]. 4. Financial Projections - The company anticipates a recovery in revenue growth, with projected revenues of 417 million, 732 million, and 1.068 billion yuan for 2025, 2026, and 2027 respectively, reflecting a year-on-year growth of 140.3%, 75.6%, and 45.9% [8][18]. - The projected earnings per share (EPS) are expected to increase from 0.49 yuan in 2025 to 0.89 yuan in 2027, indicating a strong upward trend in profitability [4][8].